A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

RECRUITING

Laura and Isaac Perlmutter Cancer Center, New York

RECRUITING

Columbia University Irving Medical Center, New York

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Roswell Park Cancer Institute, Buffalo

WITHDRAWN

Local Institution - 0023, Pittsburgh

RECRUITING

Northside Hospital, Atlanta

RECRUITING

Mayo Clinic in Florida, Jacksonville

RECRUITING

Tennessee Oncology, Nashville

RECRUITING

Mayo Clinic in Rochester, Minnesota, Rochester

RECRUITING

University Of Nebraska Medical Center, Omaha

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

RECRUITING

Mayo Clinic in Arizona - Phoenix, Phoenix

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

RECRUITING

University of Alabama at Birmingham, Birmingham

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

RECRUITING

Tom Baker Cancer Center, Calgary

RECRUITING

Princess Margaret Cancer Centre, Toronto